Cargando…
A Retrospective Analysis of the Incidence, Outcome and Factors Associated with the Occurrence of Euglycemic Ketoacidosis in Diabetic Patients on Sodium Glucose Co-Transporter – 2 Inhibitors Undergoing Cardiac Surgery
INTRODUCTION: SGLT2i is a new class of drugs used for type 2 diabetes. SGLT2i are known to cause EuKA in the perioperative period. Euglycemic ketoacidosis (EuKA) can cause life-threatening metabolic acidosis in the perioperative setting. Though the event rate of SGLT2i associated diabetic ketoacidos...
Autores principales: | Murugesan, Karthik Babu, Balakrishnan, Soundravalli, Arul, Anandhi, Ramalingam, Srinivasan, Srinivasan, Muralidharan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732953/ https://www.ncbi.nlm.nih.gov/pubmed/36254911 http://dx.doi.org/10.4103/aca.aca_47_21 |
Ejemplares similares
-
Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
por: Singh, Awadhesh Kumar
Publicado: (2015) -
Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
por: Wojtas, Caroline, et al.
Publicado: (2023) -
Euglycemic diabetic ketoacidosis by sodium glucose co-transporter inhibitors: Real but preventable concern
por: Raut, Monish S, et al.
Publicado: (2017) -
Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation
por: Tauseef, Abubakar, et al.
Publicado: (2020) -
Euglycemic Diabetic Ketoacidosis Due to Sodium–Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy
por: Pace, Devon J., et al.
Publicado: (2018)